A drug used to treat one inborn error of metabolism may be effective against another, according to a study published online March 6 in Science Translational Medicine ...

Endo announces the U.S. launch of a generic version of RAVICTI ® (glycerol phenylbutyrate), marking a significant milestone as a new generic treatment option for patients with urea cycle disorders.

Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA Methylation Pharmacokinetic data were obtained from two trials involving ...

Medunik USA is pleased to announce that as of January 1st, 2024, Pheburane® (sodium phenylbutyrate) will be covered by commercial plans representing ~80% of the US population. Pheburane® is indicated ...

The application is supported by data from the phase 2 CENTAUR trial, along with the open-label extension study. A New Drug Application has been submitted to the Food and Drug Administration (FDA) for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Hyperion Therapeutics, Inc. today announced that the Company’s phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for ...

This medication is used along with diet changes for long-term treatment of a certain inherited disorder (urea cycle disorder). Sodium phenylbutyrate helps remove a certain chemical (ammonia) from the ...

Benzoate and phenylbutyrate are widely used in the treatment of urea cycle disorders, but detailed studies on pharmacokinetics and comparative efficacy on nitrogen excretion are lacking.

Learn everything you need to know about Glycerol Phenylbutyrate-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...

ACER-001, a nitrogen-binding agent, is a powder formulation of sodium phenylbutyrate designed using a microencapsulation process. The Food and Drug Administration (FDA) has accepted for filing the New ...